Avidity Biosciences, Inc. (RNA)
NASDAQ: RNA · Real-Time Price · USD
46.15
-0.08 (-0.17%)
At close: Aug 13, 2025, 4:00 PM
45.75
-0.40 (-0.87%)
After-hours: Aug 13, 2025, 7:56 PM EDT
Avidity Biosciences Employees
Avidity Biosciences had 391 employees as of December 31, 2024. The number of employees increased by 138 or 54.55% compared to the previous year.
Employees
391
Change (1Y)
138
Growth (1Y)
54.55%
Revenue / Employee
$27,440
Profits / Employee
-$1,165,581
Market Cap
5.94B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 391 | 138 | 54.55% |
| Dec 31, 2023 | 253 | 67 | 36.02% |
| Dec 31, 2022 | 186 | 61 | 48.80% |
| Dec 31, 2021 | 125 | 54 | 76.06% |
| Dec 31, 2020 | 71 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RNA News
- 6 days ago - Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights - PRNewsWire
- 7 days ago - Novartis weighs deal for biotech Avidity Biosciences, FT reports - Reuters
- 16 days ago - Avidity Biosciences Announces Completion of Enrollment for HARBOR™, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory Submission - PRNewsWire
- 21 days ago - Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping - PRNewsWire
- 2 months ago - Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress - PRNewsWire
- 2 months ago - Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE™ Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants - PRNewsWire
- 2 months ago - Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHD - PRNewsWire
- 3 months ago - Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire